Global Leading Market Research Publisher QYResearch announces the release of its latest report “Cancer NGS Testing Platform – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Cancer NGS Testing Platform market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Cancer NGS Testing Platform was estimated to be worth US$ 597 million in 2025 and is projected to reach US$ 1567 million, growing at a CAGR of 15.0% from 2026 to 2032.
The Cancer NGS Testing Platform (NGS) is a high-throughput, highly sensitive gene sequencing technology platform capable of performing parallel sequencing and analysis of large numbers of DNA or RNA sequences in a short period of time. It is widely used in areas such as disease gene screening, personalized tumor treatment, genetic disease diagnosis, and microbial testing, providing powerful technical support for precision medicine and life science research.The market size in 2024 is expected to be US0 million.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097019/cancer-ngs-testing-platform
1. Industry Pain Points and the Shift Toward NGS-Based Precision Oncology
Traditional cancer diagnostics (single-gene PCR, immunohistochemistry, FISH) detect only known mutations and lack the breadth to identify rare or novel drivers. This limits eligibility for targeted therapies and misses actionable alterations. Cancer NGS testing platforms address this by enabling precision oncology through high-throughput sequencing of hundreds of cancer-related genes (DNA) or fusions (RNA) from tumor tissue or liquid biopsy (cfDNA). For oncologists, pathologists, and molecular labs, NGS provides comprehensive genomic profiling for personalized treatment guidance, including therapy selection (targeted, immunotherapy), clinical trial matching, and resistance monitoring.
2. Market Size, Production Volume, and Growth Trajectory (2024–2032)
According to QYResearch, the global cancer NGS testing platform market was valued at US$ 597 million in 2025 and is projected to reach US$ 1.567 billion by 2032, growing at a CAGR of 15.0%. Market hyper-growth is driven by three factors: increasing adoption of liquid biopsy for early cancer detection (Galleri, Shield), expanding targeted therapy landscape (100+ FDA-approved biomarkers), and reimbursement expansion (CMS, NCDs for NGS tests).
3. Six-Month Industry Update (October 2025–March 2026)
Recent market intelligence reveals four explosive developments:
- Multi-cancer early detection (MCED) : GRAIL’s Galleri test (methylation-based) detected 50+ cancer types with <1% false positive rate, driving insurance coverage. MCED segment grew 40% year-over-year.
- Comprehensive genomic profiling (CGP) adoption: Foundation Medicine, Guardant Health, and Exact Sciences expanded CGP coverage, replacing single-gene tests. CGP segment grew 25% in 2025.
- FDA approval of blood-based NGS companion diagnostics: Guardant360 CDx and FoundationOne Liquid CDx approved for multiple therapies (osimertinib, pembrolizumab). Regulatory approvals grew 30% year-over-year.
- Chinese NGS expansion: Berry Oncology, Genetron Health, Burning Rock, BGI Genomics, and New Horizon Health increased market share in domestic precision oncology, offering cost-competitive panels (20-30% below US pricing).
4. Competitive Landscape and Key Suppliers
The market includes MCED pioneers, CGP leaders, and Chinese NGS providers:
- GRAIL (US – multi-cancer early detection), Exact Sciences (US – cancer screening), Guardant Health (US – liquid biopsy), Akery (US), Foundation Medicine (US – tissue & liquid CGP, Roche subsidiary), Illumina, Inc. (US – sequencing platforms), Hangzhou New Horizon Health Technology Co., Ltd. (China), Berry Oncology Co., Ltd. (China), Genetron Health (Beijing) Co., Ltd. (China), Yeasen (China), Guangzhou Burning Rock Dx Co., Ltd. (China), BGI Genomics Co., Ltd. (China), Jiangsu Huayuan Biotechnology Co., Ltd. (China).
Competition centers on three axes: panel breadth (genes, fusions, TMB, MSI), limit of detection (LOD, 0.1-1% VAF for liquid biopsy), and turnaround time (7-14 days).
5. Segment-by-Segment Analysis: Type and Application
By Technology Type
- cfDNA Methylation Sequencing: Multi-cancer early detection (GRAIL, Exact Sciences). Detects cancer signal origin (tissue of origin). Highest sensitivity for early-stage cancer.
- Whole Genome Sequencing Based on cfDNA Fragmentation End Characteristics and CNV: Copy number alteration detection, fragmentation patterns. Emerging technology.
By End User
- Hospitals: Largest segment (~45% of market). Oncology centers, academic medical centers. In-house NGS testing (Illumina platforms).
- Medical Laboratories: (~30% of market). Reference labs (Labcorp, Quest) and specialized oncology labs. Send-out testing.
- Clinics: (~15% of market). Community oncology practices. Send-out testing.
- University Laboratories: (~5% of market). Research applications.
- Others: Pharma clinical trials. ~5% of market.
User case – Comprehensive genomic profiling (NSCLC) : A 62-year-old non-smoker with metastatic NSCLC had insufficient tissue for testing. Guardant360 CDx liquid biopsy detected EGFR exon 19 deletion (0.5% VAF) and no resistance mutations. Patient started osimertinib with clinical response. Tissue biopsy would have required repeat procedure (risk, delay). NGS turnaround: 10 days.
6. Exclusive Insight: NGS Applications in Oncology
| Application | Technology | Turnaround | Sensitivity | Reimbursement |
|---|---|---|---|---|
| Tissue comprehensive genomic profiling (CGP) | DNA + RNA panel (500+ genes) | 7-14 days | 5% VAF | CMS, commercial |
| Liquid biopsy CGP | cfDNA panel (70-80 genes) | 7-10 days | 0.1-1% VAF | CMS, commercial |
| Multi-cancer early detection (MCED) | cfDNA methylation | 10-14 days | 40-70% (stage I) | Limited (some commercial) |
| Minimal residual disease (MRD) | Personalized ctDNA tracking | 14-21 days | 0.001% VAF | Emerging |
| Homologous recombination deficiency (HRD) | Genomic scarring (LOH, TAI, LST) | 7-14 days | N/A | CMS (ovarian, breast) |
Technical challenge: Detecting low-allele-fraction variants in liquid biopsy (0.1-1% VAF). Noise from clonal hematopoiesis (CHIP) can cause false positives. Solutions include:
- Unique molecular identifiers (UMIs) (error correction)
- CHIP filtering (sequence white blood cells)
- Machine learning classifiers (differentiate tumor from CHIP)
User case – CHIP false positive avoidance: A liquid biopsy test detected TP53 mutation (0.8% VAF) in a patient without known cancer. Follow-up sequencing of white blood cells confirmed CHIP (not tumor). Patient avoided unnecessary imaging and anxiety. The lab’s CHIP filtering algorithm prevented false positive.
7. Regional Outlook and Strategic Recommendations
- North America: Largest market (50% share, CAGR 15%). US (GRAIL, Exact, Guardant, Foundation, Illumina, Akery). Strong reimbursement, clinical adoption.
- Asia-Pacific: Fastest-growing region (CAGR 18%). China (New Horizon, Berry, Genetron, Burning Rock, BGI, Yeasen, Huayuan). Large cancer population, expanding NGS access.
- Europe: Second-largest (20% share, CAGR 14%). Growing adoption of MCED and CGP.
- Rest of World: Latin America, Middle East. Smaller but growing.
8. Conclusion
The cancer NGS testing platform market is positioned for explosive growth through 2032, driven by liquid biopsy adoption, multi-cancer early detection, and targeted therapy expansion. Stakeholders—from platform developers to clinical labs—should prioritize comprehensive genomic profiling for therapy selection, MCED for early detection, and liquid biopsy for tissue-sparing monitoring. By enabling precision oncology and personalized treatment guidance, cancer NGS testing platforms are transforming cancer diagnosis and management.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
